Physician profile
Ashish Dalal
NPI 1801857966
$7,197.50
in general payments reported to CMS, 2019-2025
59 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,962 · 2020: $1,433 · 2021: $2,140 · 2022: $1,355 · 2023: $133 · 2024: $67.25 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $214 · Food and Beverage: $93.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $213.60 |
| Food and Beverage | $93.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $761.47 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $574.43 | 2019-2025 | Imfinzi, Tagrisso |
| Amgen INC. | $555.08 | 2019-2022 | |
| Janssen Biotech, INC. | $526.31 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $477.78 | 2019-2022 | |
| Celgene Corporation | $440.16 | 2019-2022 | |
| Pfizer INC. | $415.02 | 2019-2022 | |
| Daiichi Sankyo INC. | $277.03 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $273.68 | 2019-2024 | Welireg |
| Incyte Corporation | $272.30 | 2019-2021 | |
| Genzyme Corporation | $249.75 | 2019-2022 | |
| Genentech USA, INC. | $159.01 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.97 | 2019-2022 | |
| Octapharma USA, INC. | $146.46 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $144.46 | 2019-2022 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashish Dalal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.